Vir Biotechnology (VIR) Amortizatization of Intangibles (2018 - 2026)
Vir Biotechnology (VIR) reported Amortizatization of Intangibles of -$394000.0 for Q1 2026, up 90.36% on a YoY basis from -$206971.5 in Q1 2025, and up 74.56% sequentially from -$1.5 million in Q4 2025.
Vir Biotechnology (VIR) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Vir Biotechnology (VIR) has 9 years of Amortizatization of Intangibles data on file, last reported at -$394000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 90.36% year-over-year to -$394000.0; the trailing twelve-month figure through Mar 2026 stood at -$5.8 million (up 37.51% YoY), and the FY2025 full-year result was -$9.5 million, down 75.54% from the prior year.
- Amortizatization of Intangibles climbed to -$394000.0 in Q1 2026, from -$1.5 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $9.4 million in Q1 2023 to a low of -$4.1 million in Q1 2025.
- A 5-year average of $140235.3 and a median of -$1.1 million in 2022 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles jumped 1340.33% in 2022 and sank 1618.07% in 2025, its largest moves.
- Tracing VIR's Amortizatization of Intangibles over 5 years: stood at $7.6 million in 2022, then slumped by 117.71% to -$1.4 million in 2023, then plunged by 60.47% to -$2.2 million in 2024, then grew by 28.55% to -$1.5 million in 2025, then surged by 74.56% to -$394000.0 in 2026.
- Business Quant data shows VIR's Amortizatization of Intangibles at -$394000.0 in Q1 2026, -$1.5 million in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Vir Biotechnology | 1.31 Bn | 1.31 Bn | - | -394,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -394,000.00 |
| Mar 31, 2026 | -394,000.00 |
| Dec 31, 2025 | -1.55 Mn |
| Dec 31, 2025 | -1.55 Mn |
| Sep 30, 2025 | -1.32 Mn |
| Sep 30, 2025 | -1.32 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Dec 31, 2024 | -2.17 Mn |
| Dec 31, 2024 | -2.17 Mn |
| Sep 30, 2024 | -354,000.00 |
| Sep 30, 2024 | -354,000.00 |
| Jun 30, 2024 | -2.64 Mn |
| Jun 30, 2024 | -2.64 Mn |
| Mar 31, 2024 | -238,000.00 |
| Mar 31, 2024 | -238,000.00 |
| Dec 31, 2023 | -1.35 Mn |
| Dec 31, 2023 | -1.35 Mn |